RALIMETINIB
Ralimetinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against mitogen-activated protein kinase 14.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Postmenopause | D017698 | — | — | — | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | 1 | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Second primary neoplasms | D016609 | — | — | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RALIMETINIB |
| INN | ralimetinib |
| Description | Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly. Although originally thought to be a p38 mitogen-activated protein kinase (MAPK) inhibitor, it has since been reported that it acts instead as an epidermal growth factor receptor (EGFR) inhibitor.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; MEK (MAPK kinase) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21 |
Identifiers
| PDB | — |
| CAS-ID | 862505-00-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2364626 |
| ChEBI ID | — |
| PubChem CID | 11539025 |
| DrugBank | — |
| UNII ID | 73I34XW4HD (ChemIDplus, GSRS) |
Target
Agency Approved
MAPK14
MAPK14
Organism
Homo sapiens
Gene name
MAPK14
Gene synonyms
CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A
NCBI Gene ID
Protein name
mitogen-activated protein kinase 14
Protein synonyms
CSAID-binding protein, CSBP, cytokine suppressive anti-inflammatory drug binding protein, Cytokine suppressive anti-inflammatory drug-binding protein, MAP kinase 14, MAP kinase MXI2, MAP kinase p38 alpha, MAX-interacting protein 2, Mitogen-activated protein kinase p38 alpha, p38 MAP kinase, p38 mitogen activated protein kinase, p38alpha Exip, SAPK2a, Stress-activated protein kinase 2a
Uniprot ID
Mouse ortholog
Mapk14 (26416)
mitogen-activated protein kinase 14 (P47811)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 354 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use